|
melanoma
|
0.380 |
GeneticVariation
|
disease |
LHGDN |
Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma.
|
16538172 |
2006 |
|
melanoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Our investigations provide evidence that tyrosinase promoter CD95L constructs may be of value for selective induction of apoptosis in therapeutic strategies for melanoma.
|
15654977 |
2005 |
|
melanoma
|
0.380 |
Biomarker
|
disease |
LHGDN |
The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack.
|
15093732 |
2004 |
|
melanoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Nude mouse experiments revealed that tumorigenicity was lost when melanoma xenografts were triggered to express CD95L.
|
14668794 |
2003 |
|
melanoma
|
0.380 |
AlteredExpression
|
disease |
LHGDN |
In addition, further progression of pre-existing melanomas was inhibited and even regression was seen after induction of CD95L expression.
|
14668794 |
2003 |
|
melanoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Together the data suggest that expression of CD95L is turned on depending on the level of melanoma, and that it may tribute to creating immune privileged circumstances by initiating apoptosis of tumor filrating lymphocytes.
|
11603392 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
This is through regulation of apoptotic proteins BIM and FASL and cell-cycle regulators p21<sup>Cip1</sup> and p27<sup>Kip1</sup> We now show that an HDAC inhibitor affects the expression and localization of FOXO proteins and wanted to determine whether the combination of a MEK inhibitor with an HDAC inhibitor would increase the sensitivity of NSCLC with <i>KRAS</i> mutation.
|
29079711 |
2018 |
|
Rheumatoid Arthritis
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis demonstrates that the CD226 rs763361 and FASL rs763110 polymorphisms are associated with RA, especially in Asians.
|
25645050 |
2015 |
|
Rheumatoid Arthritis
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the -844 T>C and IVS2nt-124 A>G polymorphisms in the FasL gene related with apoptosis may increase genetic susceptibility to RA in a Turkish population.
|
23749041 |
2013 |
|
Rheumatoid Arthritis
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients.
|
21879377 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
|
21807637 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
|
21807637 |
2011 |
|
Rheumatoid Arthritis
|
0.340 |
Biomarker
|
disease |
CTD_human |
Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness.
|
20008919 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
This study was conducted to investigate the impact of functional polymorphisms in the FAS and FASL genes on the survival of early stage non-small cell lung cancer (NSCLC) patients.
|
19240174 |
2009 |
|
Rheumatoid Arthritis
|
0.340 |
Biomarker
|
disease |
LHGDN |
Soluble Fas and soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis: a Tunisian case-control study.
|
18078642 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
In subjects under age 60, for FASLG -844 C>T polymorphism, CT compared with the CC genotype, was significantly associated with increased risk of NSCLC, adjusted odds ratio (aOR) = 1.58 (1.22, 2.05), P = 0.0006 and TT aOR = 1.45 (1.01, 2.04), P = 0.04.
|
18757527 |
2008 |
|
Malignant neoplasm of lung
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Various single-nucleotide polymorphisms (SNPs) in apoptotic genes have been associated with increased risks in lung cancer, particularly FAS -1377 G>A (rs2234767), FASLG -844 C>T (rs763110), IL1B +3954 C>T Phe105Phe (rs1143634) and BAT3 Ser625Pro (rs1052486).
|
18757527 |
2008 |
|
Malignant neoplasm of lung
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the FAS-1377G>A and -670A>G and FASL-844C>T polymorphisms do not significantly affect the susceptibility to lung cancer in Koreans.
|
17014925 |
2006 |
|
Malignant neoplasm of lung
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Gene-environment interaction of FAS or FASL polymorphism and smoking associated with increased risk of lung cancer was also found.
|
15937082 |
2005 |
|
Malignant neoplasm of lung
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Because CASP8 is a key component of the death-inducing signaling complex (DISC) when specific death receptors (including DR4, DR5, FAS) are activated by their specific ligands (TRAIL/FASL), we examined expression of the components of the DISC complex in lung cancer cell lines.
|
12466971 |
2002 |
|
Malignant neoplasm of lung
|
0.340 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of prostate
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that the FAS -1377G>A, -670A>G, and FASL -844T>C polymorphisms are associated with risk of prostate cancer (PCa).
|
21557277 |
2011 |
|
Lung Neoplasms
|
0.330 |
AlteredExpression
|
group |
LHGDN |
Serum levels of sFas and sFasL during chemotherapy of lung cancer.
|
17704746 |
2007 |
|
Malignant neoplasm of prostate
|
0.330 |
Therapeutic
|
disease |
CTD_human |
Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
|
17875776 |
2007 |
|
Lung Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.
|
15937082 |
2005 |